ImmunityBio (IBRX) Short term Debt (2015 - 2021)

ImmunityBio (IBRX) has 7 years of Short term Debt data on file, last reported at $8.7 million in Q3 2021.

• On a quarterly basis, Short term Debt rose 541.37% year-over-year to $8.7 million in Q3 2021; TTM through Sep 2021 was $8.7 million, a 541.37% increase from a year earlier, with the FY2020 full-year figure at $14.8 million, up 2953.09% from the prior year.
• Short term Debt for Q3 2021 stood at $8.7 million, down from $16.7 million in the prior quarter.
• Over the last five years, Short term Debt for IBRX reached as high as $17.8 million in Q1 2021 and fell as low as $486000.0 in Q4 2019.
• Historically, Short term Debt has averaged $4.5 million across 5 years, with a median of $2.1 million in 2017.
• Across the five-year window, Short term Debt sank 71.34% in 2019 and jumped 2953.09% in 2020, its largest moves.
• Year by year, Short term Debt stood at $2.4 million in 2017, then slipped by 28.23% to $1.7 million in 2018, then sank by 71.34% to $486000.0 in 2019, then soared by 2953.09% to $14.8 million in 2020, then tumbled by 41.39% to $8.7 million in 2021.
• Per Business Quant data, the three most recent Short term Debt figures were $8.7 million in Q3 2021, $16.7 million in Q2 2021, and $17.8 million in Q1 2021.